By Susan Buckles – Mayo Clinic –
Mayo Clinic’s Center for Regenerative Biotherapeutics is collaborating with the biotech firm HepaTx on an experimental therapy to regenerate tissue in patients with late-stage liver disease. This new technology takes mesenchymal stem cells from adipose (fat) tissue and coaxes them to function like hepatocyte (liver) cells. The purpose of the collaboration is to move this technology to early clinical trials and study its effect on people with liver damage from alcohol-related hepatitis.
